Abstract | OBJECTIVE: METHODS: Fourteen patients with crystal proven pseudogout presenting with an acute attack within 5 days of onset were treated with intramuscular triamcinolone acetonide 60 mg and followed for 30 days. Patients with inadequate response were eligible for a 2nd triamcinolone acetonide injection on Day 1-2. RESULTS: Twelve patients had contraindication to nonsteroidal antiinflammatory agents ( NSAID). Acute arthritis was monoarticular in 10 patients, and involved 2 or more joints in 4 patients. All patients had good clinical response to triamcinolone acetonide based on restoration of near baseline joint range of motion and joint circumference, and at least 50% improvement in patient and physician global assessment. Major clinical improvement occurred by Day 1-2 (2 patients), Day 3-4 (11 patients), and Day 10-14 (one patient). Six patients required a 2nd triamcinolone acetonide injection on Day 1-2. Toxicities were not observed. CONCLUSION:
|
Authors | D W Roane, M D Harris, M T Carpenter, D R Finger, M J Jarek, J A Alloway, A R Erickson, W E Venanzi, T J Drehmer |
Journal | The Journal of rheumatology
(J Rheumatol)
Vol. 24
Issue 6
Pg. 1168-70
(Jun 1997)
ISSN: 0315-162X [Print] Canada |
PMID | 9195527
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents
- Triamcinolone Acetonide
|
Topics |
- Aged
- Aged, 80 and over
- Anti-Inflammatory Agents
(therapeutic use)
- Chondrocalcinosis
(drug therapy)
- Female
- Humans
- Injections, Intramuscular
- Male
- Middle Aged
- Prospective Studies
- Triamcinolone Acetonide
(therapeutic use)
|